Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Challenges in Gaucher disease: Perspectives from an expert panel.
Journal: Molecular genetics and metabolism
Published: September 28, 2024
Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
Journal: American journal of hematology
Published: May 19, 2022
Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease.
Journal: Molecular genetics and metabolism reports
Published: October 03, 2020
Gaucher disease and SARS-CoV-2 infection: Emerging management challenges.
Journal: Molecular genetics and metabolism
Published: April 20, 2020
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Journal: Blood cells, molecules & diseases
Published: April 05, 2019
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Journal: Blood cells, molecules & diseases
Published: February 26, 2018
Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Journal: American journal of hematology
Published: March 15, 2017
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Journal: Molecular genetics and metabolism reports
Published: August 04, 2016
Gaucher disease and comorbidities: B-cell malignancy and parkinsonism.
Journal: American journal of hematology
Published: June 23, 2015
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Journal: Lancet (London, England)
Published: March 31, 2015
Last Updated: 09/26/2026